Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Mogol Horde is out again.
They all really just need to stop the with sh*t posting.
Ask yourself - why would someone post over and over and over but say nothing of substance?
There are terrific posters out there, who have real info. Still would prefer a PR or two from ENZC...(sigh), but there are some real sh*t posters.
Please just focus on the company - show more information, less opinion.
Breadcrumbs, I love it. Curious..do you have a link?
Abner, Makindatcash - These breadcrumbs are awesome. Problem is that there is such a lack of PR from ENZC and so much speculation (a TON on this board) that it's REALLY hard to figure out what's really happening. There are SEC standards for disclosure of release of key material. I follow ENZC and like the breadcrumbs, but would really prefer normal disclosures. The silence is infuriating.
This process is like getting your news by reading the notes off the bathroom wall at a local gas station (or listening to CNN - lol).
Abner, your reference could be a really hearty breadcrumb. Feeds deserved optimism.
Can you provide a link?
This! Keep those breadcrumbs coming.
We all hope for better PR, but the company has LOTS of public statements and evidence.
Onward!
Doggone is correct. An 8-K could be put out and would be a proper SEC filing. Remember, one was put out in 2019.
Chandra's concept of "unnecessary" is subjective - maybe inexperience? ENZC does have to disclose material events. There were relevant subsequent event disclosures on the 6-30 OTC report because all of those events were material. But, no press release was put out.
Doggone is also correct about Mutat's post (the end is the best):
Summarizing the results from the present clinical trial, we can draw the following conclusions: 1. The application of the product ITV-1-lmmunH shows good efficacy in patients with HIV-1 infection in its various stages - in 21 of them (68%) from the main group we note an increase in CD4 + T- lymphocytes; in 16 of them the increase is accompanied by an increase in the index CD4/CD8 and CD4%, which corresponds to a reduction in the immune activation. The increase in these parameters is statistically significant compared to the control group. The absolute number and the relative share of C08 + T lymphocytes is decreasing, too. 2. We observe a very good virological effect – the viral load in 80.5% of the patients is below the threshold of detection (however, we have no comparison to the control group). 3. The application of the product ITV-1-lmmunH is well tolerated - only one patient manifested allergic dermal response. With regard to none of them we found variations in the hematological and biochemical parameters, neither did we establish clinically significant abnormal vital signs. The Report was prepared by Assoc. Prof. Dr. Ivaylo Elenkov, MD, Chief researcher. Dated: 23.11.2
Samsung is a better partner than the one replaced
Thank goodness the Lonza thing was only a disclosure error, and not something of importance. Frankly, Lonza was replaced by a better partner: Samsung.
3rd party verification is BETTER than a PR.
Especially from a giant like Samsung.
My guess is that CC is a newbie public CEO, was a bit burned by Lonza (which if you noticed, was the last PR issued by ENZC), and he feels like Samsung PR is PLENTY. CC is an intelligent guy, but there is a learning curve for public company requirements - ESPECIALLY in the penny stock world.
A humble mea culpa would have gone a loooooooong way, rather than the "loose lips sink ships" attitude that ENZC seems to have chosen.
CC issued a company update in response to earlier poster attacks - but an error by the company results in crickets? Let's just hope the company gets over the PTSD of making a disclosure error and learns from its errors. Silence is deadly when everything is based on speculation.
Sadly, bad outcomes are easier to believe than positive. Investor's unmet expectations, breed skepticism - mine too!
Let's just look for those breadcrumbs - like third party verification!
Onward!
Great analysis - Savov is a fool
HangGliding Jesus is correct. ENZC did indeed file suit to shut this joker up.
He is also correct on point #2 - ENZC is working to recover the shares from him.
Savov will do nothing, because he would have to bring suit in the US - and he does not want to do that.
He's just an idiot trying to get something for nothing. that's why ENZC is bringing suit. But, if suit dismissed, no biggie.
More Breadcrumbs….
More breadcrumbs...sure wish ENZC would do PR (sigh)
We have created Universal, Durable, Broadly Neutralizing Monoclonal Antibodies. 2 Million isolates were analyzed and confirmed that target sites were conserved in ALL #VOC and #VOI . #Delta, #Lambda, #Alpha, #Beta, & #Gamma. Our #MonoclonalAntibodies prevent "virus escape" #AI
— Gaurav Chandra M.D. (@drgauravchandra) October 18, 2021
Samsung, Intel, trials underway, veterinarian initiatives...all good. And all the things that Chandra alluded to in the past. They should be announced soon.
Can we all agree that CC is terrible at PR? But, those bread crumbs are out there.
Look at these bread crumbs. The Chandra text on the vet market, the Samsung announcement, the Intel announcement, the PCBOA audit coming. Yes, ENZC should be clearer, but there is a ton of bread out there. Sadly, allows for the Mongol Hordes to keep coming....but, there are many positives here.
VWAP above closing price - two days running?
Hmmm. The short shifters are out in force. See how the manipulation works - don't the Mongol Hordes have to cover their positions by the 15th and 30th? Can someone educate us?
Scavenger Hunt. Follow the breadcrumbs
There is so much good news, but it’s hiding. Ugh. Look what I found.
We are currently focussing on these veterinary and aquatic species. I hope that answers your question. pic.twitter.com/rIBQxQWFxT
— Gaurav Chandra M.D. (@drgauravchandra) October 9, 2021
No evidence of dilution.
Where is the evidence? Looks like the Short-Shrifters are mad at the positive news and are doing the "making up fairy tale" thing again.
Where did the Mongol horde go?
Hello?? Hello???
What else is out there?
I don't disagree with you, but why are they letting the shorts run the show?
I am betting (literally) that there is much more positive out there.
Why keep the market in the dark?
Making up stuff about Bulgarian boogiemen is silly.
More short-shrifters. There isn't any documentation on this. If it exists, show it. Otherwise, stop with the made up fairy tales
In the documentation category: Did you all see the Samsung press release?
https://markets.businessinsider.com/news/stocks/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2-monoclonal-antibody-therapies-1030850027
I wonder what else Cotropia has not told us about. Why are we having to get info from outside the company sources?
This PR did not come from ENZC. This is good news, but kind of unfair to the "loyal longs" that have suffered through the "butt-hurt" Era.
Looks like the Mongol Hordes that visited today were not successful
Grateful - for those who are here for the right reasons.
The "Short Shrifters" are so obvious. Trying to drive the price down every day to close their positions.
Looking forward to seeing continued rising in next 6-12 months and I just want to say thanks to those of us who are in the same boat. ENZC will be a great one.
Onward.
More short-shrifters today (sigh)
ENZC has 18 monoclonal patents and three immunotherapy patents. ITV-1 immunotherapy treatment has successfully tested in phase 3 trials with terrific results ( if the validation order had been properly produced the impact of that treatment would have already been realized).
Really hope that real investors can as see through the shorts. The “shorts” seem to be mad about last week’s presentation.
The name change mistake at Schwab caused confusion - so much ridiculous confusion.
It's clear that Schwab's listing is a mistake. Look at FINRA, OTC markets, public entities. No mention of name change.
The RobustoMed division, AS A DIVISION, was anounced in a July PR.
For the record, all PR's are formal disclosures. ENZC has been good in PR and it looks to me like ENZC has filed all OTC and regulatory reports and required governmental disclosures.
The only "farts in the wind" seem to be coming from the direction of the defendants of the Savov lawsuit.
To be clear, ENZC sued Savov, not the other way around.
ENZC focussing on moving forward and cleaning up on the side. Not bad.
Onward
The shorts are the ones who are pissed ("short-sters"?, "short-meisters"?). I'd be butt-hurt too if I shorted and the stock was up 3400% in a year and ENZC has held up pretty well over that period.
ENZC dips like all stocks. As they say in sports - the other guys ("short-shifters") get paid too. But, ENZC continues to rise.
Onward.
Lots of “Butt-hurt”. What does everyone think is their motivation?
The sentiment on the board that the TRO could cost additional shares to be issued is flat out wrong. This is just a dispute as to who controls those 72 million shares (and who can transfer them). Looks to me like ENZC is just defending one party vs Savov in the TRO.
ENZC will not have to issue any new shares, either way. Frankly, as a shareholder, I am happy that the company is defending the shareholders in a very professional way.
Stock one year ago was $0.0054 (1/2 a penny). Now, 34 times higher (3400%) The Kool Aid negative posters seem to be deliberately trying to push the stock down and are pissed the stock is popping.
Looks like JONSTONE knows what he's talking about. $38,000 is a piddle.
I would put anyone overreacting into the clown category.
I'll be looking forward to hearing Chandra tomorrow.
No real need to dig. Some existing info from previous ENZC documents: IMMB sold all of its assets to the entity that ended up being renamed Enzolytics. This included the worldwide licensing agreement issued from Zhabilov Trust the patent owner. (Harry Zhabilov was the inventor.) ENZC acquired 49% interest of IMMB BG. IMMB BG was issued a sub license for the Bulgarian territory and for the Ukraine when IMMB BG entered into the Omega agreement.
All agreements with IMMB BG were cancelled for failure to perform. The only license that is in place is the license granting exclusive rights to the patent to ENZC- including manufacturing rights.
Based on this license agreement between the Trust and ENZC, two distribution agreements have been entered into in 20021; one to the IMPL entity, which is paying for the clinical trials and EMA permitting cost and ENZC owns 50% and a second with an entity that is contributing 50% of a manufacturing facility in Bulgaria once the permit from the EMA is completed. I am sure neither of these two seasoned groups would have invested in a distributorship if there were any other license of the ITV-1 immunotherapy.
When a drug is approved by the EMA, after completing the Clinical Trials, ENZC would submit a validation order as part of the permitting process. Once the validation order is approved, then the EMA issues a PERMIT to sell the treatment in the countries accepting EMA approved drugs. Because there is a reciprocal agreement between the FDA and EMA the results of the clinical trials would be accepted by the FDA. Whether or not the FDA would issue permit to sell in the US, I am not sure. But with the EMA permit, most of the rest of the world will accept the treatment. Almost half of the worlds HIV cases are in Africa. I have to believe that the purpose of the reciprocal treaty with the EMA was seamlessness - otherwise why have the treaty?
Regardless, the process is: the clinical trials, THEN permitting. Your assumption is incorrect. To be able to be permitted to sell, clinical trials must happen first. The clinical trials being conducted by Clinic Design (engaged by IMPL) in Bulgaria; I believe they are due to start in October. Pharmalex was engaged by IMPL to design the clinical trials and obtain the relevant permits to perform those trials. ENZC engaged Danhson for manufacturing in Bulgaria. In my opinion, a massive upgrade over the prior process.
The concept of a “redo” is based on the following: The Bulgarian drug administration (under which the old trials were being conducted) joined the EMA after the validation order was produced for the old BDA clinical trial. It was not manufactured correctly in the US, which is why, in my opinion, the manufacturing has been moved to Bulgaria.
If the ITV-1 treatment passed for the BDA it only seems logical that it will pass the EMA.
I hope Chandra discusses this on the call this week.
Jack Torrance is right.
I've been following since the days of IMMB (and IMMB BG)
Seems like this TRO case is clearly about the 70+ million shares, not about any IP. Looks to me like the IP is in good shape. Remember, CC has been a patent attorney for 40 years and joined ENZC board 3 months prior to reverse merger - seems to know his stuff.
Hasn't Savov been declared mentally incompetent in a Bulgarian court? On a case of bank fraud? Isn't there a separate civil suit filed by ENZC for damages? In Chancellory Court in Delaware....
Isn't IMMB BG suing him in Bulgaria for forgery and fraud?
Haven't all the claims by Savov against the Bulgarian Senator been disproven?
Looks like this is just housecleaning - cleaning up Savov mess.
Not worried.
Onward!
The most precious of all possessions is power over ourselves.
John Locke